Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: Results from a post hoc analysis of a randomized, double-blind clinical trial

Journal of Child Neurology

Volumn 18, Issue 2, 2003, Pages 133-139

  Biton, Victor ^a  

^a Arkansas Epilepsy Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LORAZEPAM; PHENOBARBITAL; PHENYTOIN; VALPROATE SEMISODIUM; VALPROIC ACID;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALOPECIA; ARTICLE; ASTHENIA; BODY MASS; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG RESPONSE; EPILEPSY; FEMALE; HEADACHE; HEALTH HAZARD; HUMAN; INCREASED APPETITE; INSOMNIA; MALE; MENTAL INSTABILITY; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NYSTAGMUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHOOL CHILD; SOMNOLENCE; TREMOR; VERTIGO; VOMITING; WEIGHT GAIN;

EID: 0037305116     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738030180021701     Document Type: Article

References (45)

1. Styne DM: Childhood and adolescent obesity: Prevalence and significance. Pediatr Clin North Am 2001;48:823-854.
2. Micić D: Obesity in children and adolescents - a new epidemic? Consequences in adult life. J Pediatr Endocrinol Metab 2001;14:1345-1352.
3. Dwyer JT, Stone EJ, Yang M, et al: Prevalence of marked overweight and obesity in a multiethnic pediatric population: Findings from the Child and Adolescent Trial for Cardiovascular Health (CATCH) study. J Am Diet Assoc 2000;100:1149-1156.
4. McCance DR, Pettitt DJ, Hanson RL, et al: Glucose, insulin concentrations and obesity in childhood and adolescence as predictors of NIDDM. Diabetologia 1994;37:617-623.
5. Must A, Strauss RS: Risks and consequences of childhood and adolescent obesity. Int J Obes 1999;23(Suppl 2):S2-S11.
6. Pi-Sunyer FX: Medical hazards of obesity. Ann Intern Med 1993;119(7 Pt 2):655-660.
7. Bergen DC, Ristanovic RK, Waicosky K, et al: Weight loss in patients taking felbamate. Clin Neuropharmacol 1995;18:23-27.
8. Jones MW. Topiramate safety and tolerability. Can J Neurol Sci 1998;25(Suppl 3):S13-S15.
9. Ben-Menachem E, Henriksen O, Dam M, et al: Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-543.
10. Biton V, Montouris GD, Ritter F, et al: A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330-1337.
11. Novak GP, Maytal J, Alshansky A, et al: Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999;14:490-495.
12. Lampl Y, Eshel Y, Rapaport A, Sarova-Pinhas I: Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol 1991;14:251-255.
13. DeToledo JC, Toledo C, DeCerce J, Ramsay RE: Changes in body weight with chronic, high-dose gabapentin therapy. Ther Drug Monit 1997;19:394-396.
14. Lambert MV, Bird JM: Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril®). Seizure 1997;6:233-235.
15. Jallon P, Picard F: Bodyweight gain and anticonvulsants. Drug Saf 2001;24:969-978.
16. Dinesen H, Gram L, Andersen T, Dam M: Weight gain during treatment with valproate. Acta Neurol Scand 1984;69:65-69.
17. Egger J, Brett EM: Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;283:577-581.
18. Corman CL, Laung NM, Guberman AH: Weight gain in epileptic patients during treatment with valproic acid: A retrospective study. Can J Neurol Sci 1997;24:240-244.
19. Biton V, Mirza W, Mountouris G, et al: Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177.
20. Devinsky O, Vuong A, Hammer A, Barrett PS: Stable weight during lamotrigine therapy: A review of 32 studies. Neurology 2000;54:973-975.
21. Ueberall MA: Normal growth during lamotrigine monotherapy in pediatric epilepsy patients: A prospective evaluation of 103 children and adolescents. Epilepsy Res 2001;46:63-67.
22. Pellock JM: Managing pediatric epilepsy syndromes with new antiepileptic drugs. Pediatrics 1999;104:1106-1116.
23. Messenheimer J, Burns PA, Rudd GD, et al: Adjunctive lamictal (LTG) treatment is associated with stable body weight in patients with epilepsy. Epilepsia 1996;37:164.
24. Karceski S, Morrell M, Carpenter D: The expert consensus guideline series: Treatment of epilepsy. Epilepsy Behav 2001;2:A1-A48.
25. Dashiff C: Data collection with adolescents. J Adv Nurs 2001; 33:343-349.
26. Petersen AC, Leffert N: Developmental issues influencing guidelines for adolescent health research: A review. J Adolesc Health 1995;17:298-305.
27. Edwards KR, Sackellares JC, Vuong A, et al: Lamotrigine monotherapy improves depressive symptoms in epilepsy: A double-blind comparison with valproate. Epilepsy Behav 2001;2:28-36.
28. Isojärvi JIT, Laatikainen TJ, Knip M, et al: Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584.
29. Sherard SE, Steiman GS, Couri D: Treatment of childhood epilepsy with valproic acid: Results of the first 100 patients in a 6-month trial. Neurology 1980;30:31-35.
30. Clark JE, Covanis A, Gupta AK, Jeavons PM: Unwanted effects of sodium valproate in children and adolescents, in Parsonage MJ, Caldwell ADS (eds): The Place of Valproate in the Treatment of Epilepsy. London, Academic Press, 1980, 133-137.
31. Schmidt D: Adverse effects of valproate. Epilepsia 1984;25(Suppl 1): S44-S49.
32. Pijl H, Meinders AE: Bodyweight change as an adverse effect of drug treatment. Drug Saf 1996;14:329-342.
33. Vorum H, Gram L, Honoré B: Valproate and palmitate binding to serum albumin in valproate-treated patients: Relation to obesity. Epilepsy Res 1993;16:55-64.
34. Gidal BE, Anderson GD, Spencer NW, et al: Valproate-associated weight gain: Potential relation to energy expenditure and metabolism in patients with epilepsy. J Epilepsy 1996;9:234-241.
35. Breum L, Astrup A, Gram L, et al. Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain. Metabolism 1992;41:666-670.
36. Commission on Classification and Terminology, International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
37. Bao W, Srinivasan SR, Berenson GS: Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults. Circulation 1996;93:54-59.
38. McGill HC, McMahan CA, Zieske AW, et al: Association of coronary heart disease risk factors with microscopic qualities of coronary atherosclerosis in youth. Circulation 2000;102:374-379.
39. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, et al: Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388.
40. Trent EM: Obesity in adolescent girls: Emerging role of reproductive health professionals. J Reprod Med 2000;45:445-453.
41. Pietrobell A, Faith MS, Allison DB, et al: Body mass index as a measure of adiposity among children and adolescents: A validation study. J Pediatr 1998;132:204-210.
42. Himes JH, Dietz WH: Guidelines for overweight in adolescent preventive services: Recommendations from an expert committee. Am J Clin Nutr 1994;59:307-316.
43. Steiner TJ, Dellaportas CI, Findley LJ, et al: Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double-blind comparison with phenytoin. Epilepsia 1999;40:601-607.
44. Brodie MJ, Richens A, Yuen AW, et al: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-479.
45. Gilliam F, Vazquez B, Sackellares JC, et al: An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-1025.